BioSpace News Archive

Dr Korsgren to lead the research and development of Hansa’s proprietary enzyme technology platform as the Company expands also into new therapeutic areas

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care

Agena Bioscience®, a global provider of low-cost, high-throughput molecular testing solutions, announced the launch of the MassARRAY® SARS-CoV-2 Variant Panel for the detection of key SARS-CoV-2 virus strains, including the UK, South Africa, Brazil and Denmark variants.

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, reported business highlights and financial results for the fourth quarter ended December 31, 2020.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations events.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that it has commenced an underwritten public offering of $200.0 million of its common stock.

Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO, announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 7,000,000 shares of the Company’s common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter and full year ended December 31, 2020, and provided an update on the Company’s business operations and clinical development programs.

Application for Orally Administered Selective P2X3 Receptor Antagonist Based on Findings from Two Phase 3 Trials in Patients with Refractory or Unexplained Chronic Cough

VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications